Trials (Centre François Baclesse) - Revision history

Francine at 18:44, 14 December 2025

2025-12-14T18:44:57Z

← Older revision		Revision as of 18:44, 14 December 2025
Line 4:		Line 4:
	<span style="display:none">francecountry</span>		<span style="display:none">francecountry</span>
	Go back to [[Centre François Baclesse]] page		Go back to [[Centre François Baclesse]] page

			=== Trials: How to participate ===
			'''Contact information:''' [https://www.baclesse.fr/recherche-et-innovation/recherche-clinique/linvestigation/ Click here to access].


	'''NCTID''': NCT01827943		'''NCTID''': NCT01827943
Line 1,093:		Line 1,097:
	<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>		<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>
	<span style="display:none">hasCancerType::unknown</span>		<span style="display:none">hasCancerType::unknown</span>
			<span style="display:none">isTrial</span>

Lucas: Update categories.

2025-12-06T12:40:38Z

Update categories.

← Older revision		Revision as of 12:40, 6 December 2025
Line 1,072:		Line 1,072:
	<span style="display:none">hasTrialTitle::Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab</span>		<span style="display:none">hasTrialTitle::Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab</span>
	<span style="display:none">hasTrialTitle::CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma</span>		<span style="display:none">hasTrialTitle::CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma</span>
			<span style="display:none">hasCancerType::C00-D48: All neoplasms</span>
			<span style="display:none">hasCancerType::C00-C97: All cancer types</span>
			<span style="display:none">hasCancerType::C00-C14: Mouth/throat cancers</span>
			<span style="display:none">hasCancerType::C15-C26: Digestive system cancers</span>
			<span style="display:none">hasCancerType::C30-C39: Lung/chest cancers</span>
			<span style="display:none">hasCancerType::C40-C41: Bone cancers</span>
			<span style="display:none">hasCancerType::C43-C44: Skin cancers/melanoma</span>
			<span style="display:none">hasCancerType::C45-C49: Soft tissue cancer</span>
			<span style="display:none">hasCancerType::C50: Breast cancer</span>
			<span style="display:none">hasCancerType::C51-C58: Female genitalia cancers</span>
			<span style="display:none">hasCancerType::C60-C63: Male genitalia cancer</span>
			<span style="display:none">hasCancerType::C64-C68: Urinary system cancers</span>
			<span style="display:none">hasCancerType::C69-C72: Eye and brain cancer</span>
			<span style="display:none">hasCancerType::C73-C75: Thyroid and other gland cancers</span>
			<span style="display:none">hasCancerType::C76-C80: Cancers of unknown or unspecified areas</span>
			<span style="display:none">hasCancerType::C81-C96: Cancers of the blood and immune system</span>
			<span style="display:none">hasCancerType::C97-C97: Cancers in multiple locations from the start</span>
			<span style="display:none">hasCancerType::D00-D09: Early-stage cancers not yet spread</span>
			<span style="display:none">hasCancerType::D10-D36: Benign tumour</span>
			<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>
			<span style="display:none">hasCancerType::unknown</span>

Francine at 20:53, 2 December 2025

2025-12-02T20:53:05Z

← Older revision		Revision as of 20:53, 2 December 2025
Line 2:		Line 2:
	<span style="display:none">forproviders</span>		<span style="display:none">forproviders</span>
	<span style="display:none">forresearchers</span>		<span style="display:none">forresearchers</span>
			<span style="display:none">francecountry</span>
	Go back to [[Centre François Baclesse]] page		Go back to [[Centre François Baclesse]] page

Lucas: Update categories.

2025-12-02T13:58:30Z

Update categories.

Show changes

Francine at 18:39, 4 January 2024

2024-01-04T18:39:17Z

← Older revision		Revision as of 18:39, 4 January 2024
Line 15:		Line 15:
	'''Condition''': Relapsed Bladder Cancer		'''Condition''': Relapsed Bladder Cancer
	'''NCTID''': NCT01303497		'''NCTID''': NCT01303497
	'''Title''': Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas		'''Title''': [[hasTrialTitle::Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas]]
	'''Study Summary''': Efficacity of Paclitaxel in association or not with Bevacizumab in treatment of angiosarcoma		'''Study Summary''': Efficacity of Paclitaxel in association or not with Bevacizumab in treatment of angiosarcoma
	'''Sponsor''': Centre Oscar Lambret		'''Sponsor''': Centre Oscar Lambret

Francine at 18:38, 4 January 2024

2024-01-04T18:38:52Z

Show changes

Francine at 22:17, 1 December 2023

2023-12-01T22:17:32Z

← Older revision		Revision as of 22:17, 1 December 2023
Line 1:		Line 1:
			{{forpatients}}
			{{forproviders}}
			{{forresearchers}}
			Go back to [[Centre François Baclesse]] page

	'''NCTID''': NCT01827943		'''NCTID''': NCT01827943
	'''Title''': Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer		'''Title''': Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer

Francine: Created page with "'''NCTID''': NCT01827943 '''Title''': Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer '''Study Summary''': In the absence of standard treatment in this indication, this test evaluates a new drug type targeted therapy in this indication, evaluating its efficacy in terms of tumor response and survival. '''Sponsor''': Institut Bergonié '''Intervention''': Temsirolimus '''Start Date''': 2009-06 '''Last Updated''..."

2023-12-01T22:16:42Z

Created page with "'''NCTID''': NCT01827943 '''Title''': Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer '''Study Summary''': In the absence of standard treatment in this indication, this test evaluates a new drug type targeted therapy in this indication, evaluating its efficacy in terms of tumor response and survival. '''Sponsor''': Institut Bergonié '''Intervention''': Temsirolimus '''Start Date''': 2009-06 '''Last Updated''..."

Show changes